To keep our patient community informed, we are sharing the December 12, 2020 news that AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. The boards of directors of both companies have unanimously approved the acquisition. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in Q3 2021…
As you may know, Alexion is the manufacturer of eculizumab (Soliris) which is currently the only approved pharmaceutical treatment for aHUS in Canada. Time will tell what effect this acquisition will have for our community. We are hoping for the best.
Click HERE for the Businesswire story.